europe - teva pharmaceutical · pdf fileover 100 years’ experience. ... proprietary...

with you,

stepeveryof the way

Europe

Teva Europe | with you, every step of the w

ay

Teva Europe

with you,every stepof the way

For a start, we’re one of the world’s

top 10 pharmaceutical companies*, with

over 100 years’ experience.

We develop and manufacture medicines and

supplements for conditions ranging from the

common cold to symptoms associated with asthma. All in all, we

possess an extremely broad portfolio of specialty, generic and

over-the-counter medicines as well as APIs (active pharmaceutical

ingredients).

But, above all, we’re characterized by a relentless focus on patients.

Everything we do — from producing pharmaceuticals to offering numerous

other relevant services — is patient-driven. That’s how we intend to

become the most indispensable medicines company for the world.

Whoare we?

* Based on IMS data

6

7

PATIENT JOURNEYTEVA PROVIDES: INFORMATION

TEVA PROVIDES: SUPPORT

TEVA PROVIDES: PERSONALIZED PROGRAMS

TEVA PROVIDES: NURSING SERVICE

PRE-D

IAGNOSIS

DIAGNOSIS

ACCEPTANCE

ADAPTATION

B

ECOMING

A

N EXPERT

8

We touch the lives of millions of people every day, and billions* every year. After

all, everyone needs healthcare or medication at some point. We want to make sure

that, when they do, their experiences are as pleasant and fulfilling as possible.

We’re in the people businessOf course we facilitate this through our

ongoing innovation in pharmaceuticals.

In fact, patient centricity influences every-

thing from our product design to treatment

initiation, monitoring and adherence.

But we go much further, for example through

online patient support programmes for

those suffering from multiple sclerosis

and Parkinson’s disease**. Or, in this era of

well-informed and empowered patients,

by educating and helping people in a

number of different ways, including

through personal nurse services and

psychological support.

We also frequently interact with regulatory

authorities, healthcare providers, academia,

pharmacies and other key players to make

sure that patients’ interests are always at the

forefront.

* Based on internal data

** Certain countries only

We talk here about the patient

journey, but this also applies

to healthy people who use our

products because of lifestyle

choices (e.g. contraception).

9

Our medicines are used by patients

with conditions ranging from hay

fever to cancer, and from headaches

to heart disease.

Meeting an extraordinary range of needs

We specialize in areas including central

nerve system disorders, respiratory

conditions, oncology, transplantation and

pain. We help healthy people in their

lifestyle choices, for example, through

contraceptive pills or vitamin supplements.

And we continue to develop new ways

of addressing the unmet needs of

patients worldwide.

In 2013 we sold more than

1.3 billion tablets and capsules

in Europe alone.*

* Based on internal calculations

Generics

Medicines whose patents have

typically expired, but which we

produce to the same high, exacting

standards as the originals —

usually at far lower prices.

Specialty caremedicines

Proprietary brand-named medicines

that have been developed to address

unmet clinical needs.

NTE(new therapeutic entities)

NTE is the name given to new

delivery mechanisms, devices or

known molecules that we combine

or use in a novel way to improve

the quality of patients’ lives.

Over-the-counter

Everyday medicines, supplements,

ointments and other products that are

available without a prescription.

Our activities cover four main areas:

Each of these is explained in greater detail

on the following pages >

10

11

Being special in specialty medicines

Specific conditions and illnesses often require

more than just standard solutions. That’s

why we develop and manufacture specialty

medicines that make a real difference in

people’s lives all over the world.

We deliver innovative solutions for patients

and healthcare providers through our advanced

medicines, devices and services.

The six main specialty product areas

featured on the following pages are:

> Central nervous system

> Respiratory

> Oncology care & pain

> Women’s health

> Transplant

> Biologics & biosimilars

To ensure we address the unmet needs of patients,

we carry out a number of scientific collaborations

with key institutes in the field of specialty medicines.

These include:

> The National Network of Excellence in

Neuroscience (NNE)

A joint effort with Israeli academic and medical

institutions to advance neuroscience research.

> Collaborating on clinical development and dementia

research with the UK National Health Service

This initiative features a novel model created by the

NOCRI (Office for Clinical Research Infrastructure)

to streamline clinical development in the UK with

a single point of entry into the UK health system.

We will invest approximately $20 million in clinical

development in the UK and up to an additional

$1 million for basic research into dementia.

> R&D alliance for cancer DNA damage response

drugs with Cancer Research Technology Ltd

We have signed a multi-project alliance agreement

with Cancer Research Technology Ltd. (CRT),

Cancer Research UK’s technology development arm,

to research and develop first-in-class cancer drugs

that modulate DNA damage and repair response

(DDR) processes in cancer cells.

> Examining multiple pathways of neuroprotection

in Huntington’s disease

We are participating in global scientific research to

create a comprehensive understanding and drive

insights into neuroprotective therapeutic approaches

for Huntington’s disease (HD).

13

12

Realizing potential, every day

Our central nervous system (CNS) medication is aimed at freeing

patients from disruptions to their daily lives, letting them be more

than just their disease.

Central nervous systemWe aim to help patients realise their potential,

every day. An important factor in this is

matching a drug to an individual’s needs;

in other words, determining the treatment

regime that’s right for each specific situation.

To achieve this, we offer a strong portfolio

of CNS products for the treatment of

multiple sclerosis (MS), sleep disorders and

the symptoms of Parkinson’s disease.

For many patients, maintaining a normal,

active life is not only dependent on the

clinical efficacy of the medication they take,

but also on the side effects that could

potentially hold them back. We therefore

take the utmost care to ensure that

the impact of our medication is focused

as much as possible on tackling the

core problem.

Specialty care medicines

Generics

NTE (new therapeutic entities)

Over-the-counter

Central nervous system

Respiratory

Oncology care & pain

Women’s health

Transplant

Biologics & biosimilars

15

14

RespiratoryWe want to improve lives by delivering

friendly, typically accessible solutions

in areas like asthma, COPD (chronic

obstructive pulmonary disease) and RSV

(respiratory syncytial virus). We believe

there is untapped potential in existing

respiratory medicines, ready to be

unlocked if we can only improve the

way they are delivered to the lungs.

After all, an effective combination of

patient and inhaler is just as important

as the combination of drugs inside the

device. Inhaler devices should therefore

be intuitive and straightforward;

only then will patients feel completely

comfortable with them and use them

optimally. Once that happens,

healthcare professionals can tackle

respiratory conditions easier, without

having to change the medicines

they prescribe.

We have a proven track record in

respiratory care and are constantly

working on strengthening our portfolio.

Our deep pipeline has 10 clinical-stage

programmes; each represents a

considerable opportunity. In 2013 we

acquired MicroDose®, which further

complements our core programmes

in asthma and COPD. And we continue

to pursue the development of a

generic portfolio programme.

Just breathing should be easy

We’ve been present in the respiratory market for

many years, producing much-needed medicines

for millions of people. Our insightful ideas help

patients play a more effective role in their own

treatment.


Generics


Over-the-counter


Respiratory


Women’s health

Transplant


Laboratory of life

16

17

019

018

Oncology care & pain Our diverse pipeline of small molecules

and biologics holds great promise for

future therapies in hematologic malignancies,

solid tumours and supportive care.

By combining our global heritage with

therapeutic innovation, we provide more

treatment choices for patients. We want

to become the new innovative and

ambitious oncology partner of choice.

Many people around the world already

benefit from our very extensive portfolio

of innovative, biosimiliar and generic

molecules. For example, we already offer

branded and generics oncology

injectables, products to combat

side-effects like neutropenia and

treatment for breakthrough cancer pain,

which can be delivered by means of a

wearable patch to make it more

convenient for patients.

We want to build on these and other

products to become the most indispensable

oncology partner of the future. In fact,

our long-term commitment to making

innovative and technologically advanced

oncology medicines is a central pillar

of our overall strategy.

Our oncology medicines are dedicated to improving the lives of people

with cancer, through a portfolio of marketed products as well as continued

investment in the development of novel oncology therapeutics.

Improving the lives of cancer patients


Generics


Over-the-counter


Respiratory


Women’s health

Transplant


18

19


Generics


Over-the-counter


Respiratory


Women’s health

Transplant


Helping women all over the world

We develop and market many different products that are designed

to improve women’s health and well-being throughout their lives.

Women’s healthThrough listening to women all over the world and learning about their

genuine needs and wishes, we develop products that provide them with

the kind of care and help they’re looking for. Throughout the many different

stages in their life.

There are three main areas where this is evident. The first is in contraception,

where through innovation, improved access and simplicity we are supporting

this crucial life choice by offering many different ways of preventing pregnancy.

The second is menopause; providing relief to many of the symptoms

associated with what can be an extremely testing time in a woman’s life.

Thirdly, we are currently exploring ways of improving fertility that are

aimed at increasing the chances for many women who want to have children

but are encountering difficulties. Further proof that we are channelling

considerable resources into addressing women and their unique health

needs — today and tomorrow.

21

20

An affinity for life

Harnessing the power of organisms

Our goal is to be the one stop shop

for the transplant community, offering

(branded) generic and innovative

medicines to improve patient outcomes.

TransplantTransplantation is a way is offering people

a new chance in life — and in some cases

offering them a continuation of life itself.

Our medication increases the chances of

successful transplant outcomes.

We are currently building a portfolio of

products with the aim of being a one stop

shop for transplantation medication in

the near future. Ultimately, we want the

transplant community to think of us

every time, regardless of the product

or molecule required.

As well as offering medicine, we also play a

part in progressing transplantation science.

We support the development of research

aimed at progressing patient outcomes or

individualising therapies. And we encourage

initiatives to increase the number of organs

that are transplanted or transplantable.

Biologics & biosimilarsBiologics are medicines that are created by

using living organisms, such as yeasts or

proteins. In addition to developing our own

biologics, we also offer many different kinds

of biosimilars.

This sub-category of biologics is derived

from living cells but is not identical to the

original; hence the name. What you get is

the same effect — at a lower price but

with the same quality. In that sense,

biosimilars are to biologics what generics

are to branded drugs.


Generics


Over-the-counter


Respiratory


Women’s health

Transplant


23

22

€Our generic medicines are of vital importance to

the European healthcare market. By manufacturing

medicines whose patents have typically expired,

we drive down the cost because there is no need for

extensive — and expensive — research & development.

Our generic medicines are manufactured to exactly

the same demanding standards as the original

branded drugs. They also have the same effect on

the patient. The only significant difference is the price!

We are the leading generics manufacturer in Europe1.

We produce over 1000 molecules, which form the basis

for tens of thousands* of different generic medicines.

Our estimates suggest that this leads to a reduction in the

European healthcare budget by an average of €8 billion2

per year. This has two enormous benefits: it helps make

healthcare more sustainable and affordable in general.

And, because the investment costs are much lower for

generics, this frees up money for us to invest in areas

where breakthroughs are still required (see page 38).

1 Based on IMS data2 Based on EGA & internal data

* Based on internal data

Helping hundreds of millions* while saving billions2

through generics


> Generics


Over-the-counter

25

24

8 000000000


> Generics


Over-the-counter

We estimate that we save €8 billion every year from Europe’s healthcare budget through our cost-effective generic medicines*

* Based on EGA & internal data

26

27

New therapeutic entities (NTEs) is the name given to known

molecules that are combined, reformulated, delivered or used

in a novel way. We are unique in that we have both generic and

specialty molecules in-house, which we combine on an

unprecedented scale.

This increases our scope for developing NTEs that can benefit

patients in numerous ways: fewer pills are required for the

same impact, reduced side-effects, more effective delivery and

improved outcomes.

We are currently exploring NTEs in many different areas that are

of direct relevance to patients, including acute & chronic pain,

schizophrenia, glaucoma and Crohn’s disease.

New combinations mean renewed hope for patients

> Generics

> Branded/speciality

NTE (New Therapeutic Entities) <

> Over The Counter


Generics

> NTE (new therapeutic entities)

Over-the-counter

It is our

ambition to start

development of

around 10 new

NTE projects each

year to 2020

29

28

Millions of people throughout Europe use our over-the-counter products every day —

without even realizing it. That’s because we have teamed up with Procter &

Gamble in a joint venture that combines our pharmaceutical expertise with its

branding and marketing skills.

The PGT Healthcare joint venture manufactures

and markets more than 200 consumer healthcare

brands in more than 70 countries around the world.

Our portfolio includes Vicks — the world’s #1

selling cough & cold brand, ratiopharm —

the #1 OTC brand in Germany, and other leading

brands like Vibovit, Ambrobene, Hylak,

Novo-Passit and Gastal.

The OTC category is strategically important for both P&G and Teva. Our partnership with

P&G enables us to accelerate expansion into new countries and categories. Given global

trends and demographics, we are confident that this is a valuable growth engine for Teva

now and into the future.

Teaming up to empower people to care for themselves

®


Generics


> Over-the-counter

PMS 7690 PMS 367 PMS 298 PMS 431DESIGN INTENT

randallh48433_PGT_Mark with Pattern

/PROJECT EDEN/+DESIGN/48384 PGT Brand Rollout/48684_Production/48384_PGT_Mark_101411Friday, October 14, 2011

30

31

same high quality Different namesratiopharm

With its headquarters in the German town of Ulm, ratiopharm is the most widely used

and best known brand of drugs in Germany, recognized for decades as the epitome of

high quality at a reasonable price. With the ratiopharm brand Teva is leading in generics

and over-the-counter products and also offers a number of biosimilars. The ratiopharm

brand is also well known in Austria, Italy, Switzerland and Spain.

PLIVA

The largest pharmaceutical company in Croatia

and one of the largest in Southeast Europe,

PLIVA can call on over 90 years of experience.

Over 80% of the products manufactured by

PLIVA are exported.

Mepha

Mepha is the leading supplier of generic

medicines in Switzerland. It offers an extensive

range of quality medication, which gives the

desired therapeutic effect at a much lower

price than the originals.

our Teva brand, we offer

solutions to patients under a variety

of other names. The Teva group is home

to several other brands, including

ratiopharm, PLIVA and Mepha.

Inaddition to

32

33

packs sold in 2013 in Europe*

That’s an astonishing total of

3311 55 99 88 00 00 00 00 002 500* Based on internal data

Teva packs are

sold every

single minute

of every single

day in Europe,

on average*

34

35

Proud of our heritage, inspired by new possibilities

We’ve come a long way since 1901, when three young pharmacists set up a

small store in Jerusalem selling various kinds of medication. Today we employ

close to 46,000 employees that are spread across 60 countries, following an

approach best described as ‘local adaptation on a global scale’.

Our growth has been both organic and through acquisition. Within the last

two decades alone we have acquired more than 20 companies throughout

the world, whose expertise and market knowledge add value to our existing

capabilities. And we will continue to build on our strong foundations while

seeking relevant new opportunities that benefit patients.

36

37

An ongoing commitment to innovationWe reinvest approximately 7% of our revenue

into R&D worldwide. In 2012 that meant that

almost $1.5 billion channelled into developing

breakthroughs, improving existing propositions

and other activities designed to provide effective

and affordable treatment for patients.

We have a proven track record in innovation

across our chosen areas of expertise, with a

particularly strong emphasis on neurological

disorders, respiratory ailments and oncology care.

Our research activities for both generics and

specialty pharmaceuticals are closely integrated

to give synergy of integration. Work done on

generics (especially on delivery technologies)

can have equal utility in specialty medicines —

and particularly for NTEs where formulators and

analytics expertise in generics is key in the

NTE development program.

We also maintain strong partnerships with

our academic and scientific partners. For

example, the National Network for Excellence

in Neuroscience, Cancer Research Technology

and other pharmaceutical experts, healthcare

providers and insurance companies to ensure

that new developments are based on a broad

range of relevant insights.

innovation

39

38

PATIENT JOURNEYTEVA PROVIDES: INFORMATION

TEVA PROVIDES: SUPPORT

TEVA PROVIDES: PERSONALIZED PROGRAMS

TEVA PROVIDES: NURSING SERVICE

PRE-D

IAGNOSIS

DIAGNOSIS

ACCEPTANCE

ADAPTATION

B

ECOMING

A

N EXPERT

Beyond pharmaceuticals

We’ve made our name by providing high-quality pharmaceuticals for decades. But that’s not all we do. In fact, we have a

presence throughout the entire patient journey: from pre-diagnosis through diagnosis, from

acceptance & adaptation to the stage at which people become experts in their conditions.

To give just one example, in the UK

we offer support for those who have to

inject their medicine on a daily basis,

making their lives easier. We provide

further information, personalized

programmes and nurse services when required. In fact, we have

an entire European patient services department that is dedicated

to understanding patient issues, and then exploring how we can

best address them.

41

40

Why choose Teva?

As a business partner We continue to leverage the size and diversity of our

operations to bring the best quality pharmaceutical products

to patient’s doorsteps.

High standards of performance, efficiency and

cost-effectiveness

Through our extensive and efficient operational network

we can successfully maintain high standards of performance,

efficiency and cost-effectiveness. Important elements in

this include a sound knowledge of pharmaceutical production

technologies, in depth understanding of regulatory

requirements and quality management.

Strict, regulated manufacturing

The manufacture of both generic and innovative drugs is

regulated strictly and follows the relevant cGMP (current

good manufacturing practices) standards, both in the lab and

at production sites. Our European FDA certified plants have

been inspected over 200 times without incident.

Patient safety is at the heart of our agenda and is one of

our core principles. All of our medicines undergo thorough

safety monitoring and evaluation processes at every stage

of their lifecycle. We are committed to absolute transparency

in exposing the benefits and risks of our medicines, and

work in complete accordance with health authorities

around the world.

As an employerHeadquartered in the Netherlands, Teva Europe employs

approximately 15,000 people. Being active in 36 countries,

including the 28 European Union member states, we are

proud to say that our employees are the reason for our

sustained success. Their skills and dedication make us an

industry leader. Their diverse perspectives, qualifications,

and talents are key to our ongoing accomplishments.

Our company is a place where great ideas flourish.

We believe in empowering our employees, presenting

them with new challenges and letting them grow and

develop professionally.

We provide our people with:

> A wide variety of jobs and fields of expertise

> A unique creative organizational culture

> A wealth of opportunities for personal growth

Our employees enjoy prospects for genuine personal,

professional and organizational development.

43

42

We have a heritage stretching back over

100 years

Over 60 sites across Europe:> Operations> R&D> Commercial

We do business with approx. 30,000 suppliers**

Over 15,000 dedicated employees in the EU**

Teva saves an estimated €8 billion a year on the European healthcare budget***

A presence in 36 EU countries**

Quality medicines in generics, NTE, specialty and OTC

Trusted brands: Teva, ratiopharm, PLIVA, Mepha

We are a global top 10 pharmaceutical company*

On average, 2500 Teva packs are dispensed in the EU, every single

minute of every single day**

Teva Europe dispenses 1.3 billion packs per year**

* Based on IMS data ** Based on internal data *** Based on internal and IMS data

17 operating sites in the EU

Over 1000 molecules

No. 1 in generics*

The world of Europe

45

44

HQ/TV/14/0003

Teva Pharmaceuticals Europe

Piet Heinkade 107

1019 GM Amsterdam

The Netherlands

P.O. Box 16416

1001 RM Amsterdam

The Netherlands

Tel: +31 (0)20 2193 200

[email protected]

www.tevapharm.com

Europe

Teva Europe | with you, every step of the w

ay

europe - teva pharmaceutical · pdf fileover 100 years’ experience. ... proprietary...

Documents